No impact of cancer and plague-relevant FPR1 polymorphisms on COVID-19 - Centre de recherche des Cordeliers
Article Dans Une Revue OncoImmunology Année : 2020

No impact of cancer and plague-relevant FPR1 polymorphisms on COVID-19

Résumé

Formyl peptide receptor 1 (FPR1) is a pattern-recognition receptor that detects bacterial as well as endogenous danger-associated molecular patterns to trigger innate immune responses by myeloid cells. A single nucleotide polymorphism, rs867228 (allelic frequency 19-20%), in the gene coding for FPR1 accelerates the manifestation of multiple carcinomas, likely due to reduced anticancer immunosurveillance secondary to a defect in antigen presentation by dendritic cells. Another polymorphism in FPR1, rs5030880 (allelic frequency 12-13%), has been involved in the resistance to plague, correlating with the fact that FPR1 is the receptor for Yersinia pestis. Driven by the reported preclinical effects of FPR1 on lung inflammation and fibrosis, we investigated whether rs867228 or rs5030880 would affect the severity of coronavirus disease-19 (COVID-19). Data obtained on patients from two different hospitals in Paris refute the hypothesis that rs867228 or rs5030880 would affect the severity of COVID-19.
Fichier principal
Vignette du fichier
No impact of cancer and plague-relevant FPR1 polymorphisms on COVID-19.pdf (849.18 Ko) Télécharger le fichier
Origine Publication financée par une institution
licence

Dates et versions

hal-04438626 , version 1 (04-09-2024)

Licence

Identifiants

Citer

Adriana Petrazzuolo, Julie Le Naour, Erika Vacchelli, Pascale Gaussem, Syrine Ellouze, et al.. No impact of cancer and plague-relevant FPR1 polymorphisms on COVID-19. OncoImmunology, 2020, 9 (1), pp.1857112. ⟨10.1080/2162402X.2020.1857112⟩. ⟨hal-04438626⟩
13 Consultations
0 Téléchargements

Altmetric

Partager

More